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INTRODUCTION
For esthetic purposes botulinum toxin A (BTX-A) began to be 
used in 1990, to reduce the wrinkles caused by muscle facial lines 
strength(1). Its effect starts three to four days after application and 
remains four to six months, when, it is believed, regeneration or proli-
feration of new nerve terminals occurs and promote and re-establish 
the motor endplate(1,2).
Over 2.5 million esthetic procedures using BTX-A were performed 
in 2008 in the USA. BTX-A use has been the most popular cosmetic 
procedure since 2000, and the number of procedures increased 3681% 
since 1997(3). Consequently, complications have also increased(1,3-8).
Contraction of the lateral orbicularis muscle is responsible for the 
creation of active lines or wrinkles that radiate from the lateral can-
thal angle, which are commonly referred to as “smile” lines or “crow’s 
feet”. Beside eyelid ptosis, a well known complication, the treatment 
of these wrinkles with BTX-A can bring an undesirable side effect in 
extraocular muscles (EOM) causing paralytic strabismus and diplo-
pia(1,5,9). The diplopia generates difficulties to perform daily tasks or 
work activities. 
Paralysis of extraocular muscle can be caused by poor technique, 
diffusion of BTX-A by the septum or infiltration of large volumes of 
BTX-A in low concentration(1,4,6,8).
In this report we present two patients followed between Novem-
ber 2009 and September 2010, with diplopia secondary to periocular 
application of BTX-A for cosmetic treatment of “crow’s feet” (Table 1). 
The purpose of this article is to introduce an alternate technique for 
the treatment of this complication. Both patients were fully informed 
of the risks of this procedure and had signed an informed consent 
according to the Declaration of Helsinky.
CASE REPORTS
Case 1
A 41-year-old woman, who had BTX-A application in the face 10 
days before, presented with diplopia starting one day prior to con-
sultation. The dosage that was used was not known and she denied 
systemic pathologies. Best corrected visual acuity was 20/20 in both 
eyes. Cover test with prisms, left eye (LE) fixing, showed in primary 
position esotropia of 14 prism diopters (PD) which increases in right 
gaze and diminishes in left gaze. 10 days after onset of diplopia she 
was treated with Botox® (Allergan, Irvine, CA) application into the 
right medial rectus muscle (2.5 U - 0.05 ml) with topical anesthesia 
and Mendonça’s forceps. Seven days after the procedure she descri bed 
di plopia only on extreme lateroversions. Three months post BTX-A 
intramuscular injection she remained asymptomatic and recognized 
stereoacuity of 40 s arc at Titmus test.
Case 2
A 53-year-old woman, complained of diplopia noticed 14 days 
after BTX-A application for wrinkle elimination. The dosage that was 
used was not known. Three days after development of symptoms she 
was evaluated by an ophthalmologist. Prior to this, she underwent 
a complete neurological evaluation that was normal. Ophthalmic 
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ABSTRACT
A new technique for the treatment of diplopia secondary to cosmetic botulinum 
to xin A use is described. In this interventional case reports, two consecutive patients 
who developed diplopia after periocular cosmetic use of botulinum toxin A were 
treated with intramuscular botulinum toxin A injection into the antagonist ex traocular 
muscle. Diplopia resolved in both patients in less than 1 week with no side effects 
or complications. In conclusion, the injection of intramuscular botulinum toxin A is 
an encouraging option for treatment of diplopia secondary to botulinum toxin A 
use for facial lifting. 
Keywords: Botulinum toxins, type A/adverse effects; Strabismus; Diplopia; Neuro-
muscular agents/administration & dosage; Humans; Female; Adult; Case reports
RESUMO
Uma nova técnica para tratamento de diplopia secundária ao uso estético da toxina 
botulínica A é descrito. Nestes relatos de casos, dois pacientes consecutivos que desen­
volveram diplopia após uso cosmético de toxina botulínica A periocular foram tratados 
com injeção de toxina botulínica A no músculo extraocular antagonista. A diplopia 
melhorou em menos de uma semana nos dois pacientes, sem efeitos colaterais. Con­
sideramos o uso de injeção intramuscular de toxina botulínica A como uma possível 
opção para o tratamento da diplopia secundária ao uso da toxina botulínica A para 
rejuvenescimento facial.
Descritores: Toxinas botulínicas tipo A/efeitos adversos; Estrabismo; Diplopia; Fár macos 
neuromusculares/administração & dosagem; Humanos; Feminino; Adulto; Re latos de casos
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examination revealed low myopia and best corrected visual acuity of 
20/25 in both eyes. Cover test with prisms showed in primary posi-
tion esotropia of 14 PD when right eye fixing and esotropia of 18 PD 
when left eye fixing. Ductions showed slight limitation (-1) of lateral 
rectus muscles of both eyes. The rest of the ophthalmological exam 
was unremarkable. Occlusive treatment was not tolerated by the 
patient. Faced with major complaints by her diplopia we proposed 
and carried out (12 days after symptoms onset) Botox® application 
of 2.5 U (0.05 ml) in the right medial rectus muscle with topical 
anesthesia and Mendonça’s forceps. Two days after treatment she 
described total recovery of diplopia and at subsequent evaluations 
she remained asymptomatic. Stereoacuity of 40 s arc (Titmus test) 
and no movements on cover tests were observed.
DISCUSSION
The use of BTX-A for treatment of diplopia secondary to cosmetic 
BTX-A application was effective. To our knowledge, there is not similar 
data published in the literature. 
The intervention and follow-up of two patients with diplopia star-
ted 9 and 14 days after BTX-A application for facial esthetic treatment 
of crow’s feet. They reported significant discomfort and difficulty in 
performing their daily and work activities.
In both cases we found esotropia secondary to paresis of lateral 
rectus muscle probably by diffusion of BTX-A applied into the orbicu-
laris muscle at lateral canthus.
Patients had their diplopia treated with BTX-A application into 
their medial rectus muscle, antagonist of the muscle that was affec-
ted by cosmetic procedure (lateral rectus). They presented a rapid im-
provement of symptoms (7 and 2 days after treatment). Usually, the 
time of improvement with expectant management occurs around 7 
to 10 weeks after cosmetic treatment(6). Shortening the duration of 
diplopia can lead to an important positive impact in the quality of 
life of patients.
We performed this treatment only in cases which there was a 
recent involvement of the lateral rectus muscles. This made planning 
easier because this treatment is similar to that used for treating cases 
of sixth cranial nerve palsy.
By choosing the same drug used in the procedure that caused 
the diplopia and performing treatment a few days after the first pro-
cedure, we believed that the time in which the muscles suffer toxin 
effect would be similar. This actually occurred and the patients were 
asymptomatic throughout the postoperative follow-up.
From the foregoing, the authors propose that patients that will 
undergo a procedure with BTX-A for cosmetic purposes should be 
warned about the possibility of developing postoperative diplopia. 
If this occurs, referring the patient to an ophthalmologist as soon as 
possible is imperative for appropriate management. The ophthal-
mologist should be experienced in the treatment of strabismus and 
should define the best treatment choice for each case, which could 
be a conservative management, use of ocular occlusion(8), glasses 
with prismatic lenses or use of BTX-A injection into the antagonist 
mus cle as described in this article. Further studies are needed to con-
firm efficacy and safety of this new therapeutic approach.
Literature searCh
A PubMed literature search from 1980 to present was completed 
to identify existing reports of complications with the use BTX-A for 
esthetic and its treatment. Search terms included botulinun toxin com ­
plications, strabismus, diplopia, esthetic. Articles references in papers 
and standard textbooks were also consulted.
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Table 1. Cases description, injured muscle and performed treatment








Case 1 09 days Lateral rectus Absent Botox® application  
in MR**
Total recovery 7 days  
after treatment 
Case 2 14 days Bilateral lateral rectus Absent Botox® application  
in MR**
Total recovery 2 days  
after treatment
*= days after BTX-A application for facial esthetic treatment 
**= MR medial rectus
